Remedium Bio has developed the Prometheus™ adjustable gene therapy platform, which enables the localized delivery of therapeutic genes through a single subcutaneous injection, allowing for precise post-treatment dose adjustments. The company addresses significant clinical needs by providing durable alternatives to protein-based therapies for conditions such as obesity, type 2 diabetes, and osteoarthritis, potentially reducing treatment costs and improving patient outcomes.
Funding
Funding not disclosed
LVFounders
Product
Problem
Many protein-based therapies for chronic conditions like obesity, type 2 diabetes, and osteoarthritis require frequent subcutaneous injections, leading to high treatment costs and inconsistent patient adherence. Current treatments often fail to durably reverse disease progression, necessitating repeated interventions and potentially leading to complications.
Solution
Remedium Bio is developing the Prometheus™ adjustable gene therapy platform to provide durable alternatives to frequent protein-based injections. This platform enables localized delivery of therapeutic genes through a single subcutaneous injection, with the potential for post-treatment dose adjustments. By utilizing well-characterized vectors like adeno-associated virus (AAV) and lipid nanoparticles (LNP), the platform aims to offer safe, effective, and long-lasting treatments for diseases with large unmet clinical needs. The localized delivery system ensures high specificity and minimizes systemic exposure, potentially improving safety profiles compared to existing therapies. Remedium Bio's pipeline includes disease-modifying treatments for endocrinology, immunology, neurology, and musculoskeletal diseases.
Target Audience
The primary target audience includes patients with chronic conditions such as obesity, type 2 diabetes, stroke, and osteoarthritis, as well as healthcare providers seeking durable and cost-effective treatment options.
Features
- Prometheus™ adjustable gene therapy platform enabling localized therapeutic gene delivery.
- Single subcutaneous injection for durable treatment, replacing frequent protein injections.
- Post-treatment dose adjustment capabilities for personalized therapy.
- Utilizes adeno-associated virus (AAV) and lipid nanoparticles (LNP) vectors for safe and effective gene delivery.
- Modular application of proven fundamentals to treat well-characterized pathologies.
- Pipeline includes treatments for obesity, type 2 diabetes, stroke, and osteoarthritis.
- Focus on regenerative therapeutics targeting diseases of aging and large clinical unmet needs.